RETL2 Inhibitors
RETL2 inhibitors refer to a category of compounds that inhibit the activity of the RETL2 protein. RETL2, also known as resistin-like molecule beta, is a protein encoded by the RETNLB gene in humans. It is a member of the resistin family of proteins, which have been identified in various species, including mice and humans. These proteins play roles in several physiological processes, primarily involving inflammation and energy homeostasis. RETL2, in particular, has been observed to be expressed in specialized epithelial cells of the colon, where it can function in the modulation of inflammatory responses.
The chemical structures and mechanisms of action of RETL2 inhibitors can vary. They are designed to target the RETL2 protein, reducing or blocking its activity. The exact mechanisms of these inhibitors, whether they function by binding directly to the protein, affecting its synthesis, or interfering with its downstream signaling, can differ based on the specific compound. The specificity and selectivity of RETL2 inhibitors are crucial since targeting other members of the resistin family or other unrelated proteins can lead to undesirable off-target effects. The discovery and development of RETL2 inhibitors have been a focal point of biochemical and molecular research, aiming to better understand the role of RETL2 in physiological and pathological processes. By delving deeper into the molecular interactions and dynamics of these inhibitors, researchers hope to unveil new insights into the underlying biology and potential applications of these chemical compounds.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib is a small molecule kinase inhibitor that can block the activity of the RETL2 (also known as RET) protein by binding to its kinase domain. This binding prevents the activation of RETL2 and its downstream signaling, which is involved in promoting cell growth and proliferation. Vandetanib has been studied in the research of thyroid cancer and has shown efficacy in inhibiting the RETL2 pathway. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $92.00 $204.00 | 1 | |
Cabozantinib is a multi-kinase inhibitor that targets several receptor tyrosine kinases, including RETL2. By inhibiting RETL2, Cabozantinib interferes with the signaling pathways responsible for cell survival, angiogenesis, and metastasis. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $178.00 $648.00 $1657.00 | 3 | |
Lenvatinib is another multi-kinase inhibitor that inhibits RETL2 as part of its mechanism of action. By blocking RETL2 activity, Lenvatinib can reduce the growth of blood vessels in tumors and inhibit cancer cell proliferation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that targets several kinases, including RETL2. It inhibits the phosphorylation and activation of RETL2, thus disrupting the downstream signaling pathways involved in tumor growth and angiogenesis. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $193.00 $510.00 $1072.00 | 4 | |
Sunitinib is a multi-kinase inhibitor that can block RETL2's activity by binding to its kinase domain. In doing so, it inhibits the proliferation and survival of cancer cells and interferes with angiogenesis. | ||||||
Apatinib | 811803-05-1 | sc-480044 | 10 mg | $380.00 | ||
Apatinib is a small molecule inhibitor primarily designed to target vascular endothelial growth factor receptor 2 (VEGFR2), but it may also have some inhibitory effects on RETL2. By limiting angiogenesis, it indirectly affects the tumor microenvironment and may hinder RETL2-dependent tumor growth. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Regorafenib is a multi-kinase inhibitor that includes RETL2 in its spectrum of targets. It disrupts RETL2-mediated signaling pathways, which are critical for tumor cell proliferation and survival. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $172.00 $964.00 | 2 | |
Ponatinib is a tyrosine kinase inhibitor with activity against RETL2. It can prevent RETL2 from becoming constitutively active, which is often seen in certain types of cancer. Thus, it inhibits downstream signaling pathways related to cell growth. | ||||||
Dovitinib, Free Base | 405169-16-6 | sc-396771 sc-396771A | 10 mg 25 mg | $170.00 $350.00 | ||
Dovitinib is another multi-kinase inhibitor that can target RETL2. It hinders RETL2-driven signaling pathways involved in cell growth and angiogenesis. | ||||||